Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Ginkgo Bioworks Holdings Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.53 (market cap $2.14B), while Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M). The key difference: AMC ENTERTAINMENT HOLDINGS, INC. is far larger — about 4.2× Ginkgo Bioworks Holdings Inc's market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| AMC | DNA | |
|---|---|---|
Market Cap | $2.14B | $505.73M |
Sector | Media | Health |
52-Week High | $3.15 | $16.14 |
52-Week Low | $0.95 | $5.48 |
Enterprise Value | $9.08B | $607.68M |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $2.555, up 5.58% today, with a bullish technical signal and recent earnings beats. The company reported record Q2 2026 revenue and EBITDA, driven by strong box office performance and premium screen growth. However, it remains unprofitable with a net income margin of -10.59% and negative shareholder equity of -$1.76 billion as of 2024. Cash flow trends show improvement, with projected positive operating cash flow of $219 million in 2026.
Outlook is mixed; operational recovery and analyst consensus price target of $3.00 offer upside, but high debt and persistent losses pose significant risks. Investor sentiment is buoyed by record-breaking weekends and international expansion, yet volatility from meme-stock status and competitive pressures require caution.
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
